{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:17:40Z","timestamp":1795094260878,"version":"4.10.2"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024-YJ-226-J-027"],"award-info":[{"award-number":["2024-YJ-226-J-027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372106"],"award-info":[{"award-number":["82372106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222035"],"award-info":[{"award-number":["82222035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502547"],"award-info":[{"award-number":["82502547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFA0923000"],"award-info":[{"award-number":["2025YFA0923000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515011290"],"award-info":[{"award-number":["2025A1515011290"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2025AFD794"],"award-info":[{"award-number":["2025AFD794"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.biomaterials.2026.124320","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:12:59Z","timestamp":1779203579000},"page":"124320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Modularly designed hybrid vesicles as dual-adjuvant nanovaccines for cancer immunotherapy"],"prefix":"10.1016","volume":"335","author":[{"given":"Yuanwei","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lefan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfa","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5010-0729","authenticated-orcid":false,"given":"Lang","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biomaterials.2026.124320_bib1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124320_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124320_bib3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41590-025-02308-2","article-title":"Cancer vaccines as enablers of immunotherapy","volume":"26","author":"Khleif","year":"2025","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124320_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124320_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2016","journal-title":"Nat. Mater."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124320_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","article-title":"Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria","volume":"6","author":"Yue","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124320_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","article-title":"A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124320_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41565-025-01952-x","article-title":"A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy","volume":"20","author":"You","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124320_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41565-025-01931-2","article-title":"Engineering pyroptotic vesicles as personalized cancer vaccines","volume":"20","author":"Li","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124320_bib10","article-title":"Inhalable nanovaccine based on bioengineered bacteria-derived membrane vesicles against lung metastasis","volume":"37","author":"Miao","year":"2025","journal-title":"Adv. Mater."},{"issue":"601","key":"10.1016\/j.biomaterials.2026.124320_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc2816","article-title":"Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines","volume":"13","author":"Chen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124320_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102076","article-title":"Genetically engineered eukaryocyte-bacteria hybrid membrane-camouflaged nanoemulsion for three-pronged synergistic cancer therapy","volume":"54","author":"Zhang","year":"2024","journal-title":"Nano Today"},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124320_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201908185","article-title":"A hybrid eukaryotic-prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination","volume":"32","author":"Chen","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124320_bib14","first-page":"197","article-title":"Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation","volume":"56","author":"Wang","year":"2026","journal-title":"Bioact. Mater."},{"issue":"29","key":"10.1016\/j.biomaterials.2026.124320_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202201306","article-title":"Bifunctional fusion membrane-based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells","volume":"32","author":"Ke","year":"2022","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6774","key":"10.1016\/j.biomaterials.2026.124320_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/science.ady5362","article-title":"Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity","volume":"390","author":"Xie","year":"2025","journal-title":"Science"},{"issue":"38","key":"10.1016\/j.biomaterials.2026.124320_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202504155","article-title":"Bacterial foreignization nanosystem elicits multi-phenotypic T cells for antitumor immunity","volume":"12","author":"Zhuang","year":"2025","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124320_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","article-title":"Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity","volume":"19","author":"Liu","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib20","article-title":"Harnessing enucleated cancer cells as Trojan horse cell vaccines","volume":"5","author":"Fang","year":"2024","journal-title":"Cell Rep. Phys. Sci."},{"issue":"8061","key":"10.1016\/j.biomaterials.2026.124320_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41586-025-08758-w","article-title":"STING agonist-based ER-targeting molecules boost antigen cross-presentation","volume":"641","author":"Wang","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124320_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.biomaterials.2026.124320_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902626","article-title":"Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124320_bib25","article-title":"Super-adjuvant nanoparticles for platform cancer vaccination","volume":"6","author":"Kane","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biomaterials.2026.124320_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102061","article-title":"A DNA-polymer hybrid nanocomplex based bi-adjuvant vaccine for tumor immunotherapy","volume":"54","author":"Li","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.biomaterials.2026.124320_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123524","article-title":"Genetically modified bacterial vesicles with interferon-\u03b3 and tumor antigen remodel anti-tumor cellular immunity by modulating dendritic cells","volume":"324","author":"Fu","year":"2026","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124320_bib28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41551-025-01380-1","article-title":"Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading","volume":"9","author":"Qdaisat","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124320_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124320_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s43018-024-00889-9","article-title":"Systemic IFN-I combined with topical TLR7\/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells","volume":"6","author":"Sanlorenzo","year":"2025","journal-title":"Nat. Cancer"},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124320_bib32","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"Le Bon","year":"2003","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124320_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.biomaterials.2026.124320_bib34","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","article-title":"Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment","volume":"185","author":"Baharom","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124320_bib35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib36","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib37","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1038\/s41467-025-61699-w","article-title":"A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124320_bib38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124320_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124320_bib40","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2011.37.5394","article-title":"Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma","volume":"30","author":"Tarhini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124320_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Kruit & gerrit stoter side effects of interferon-\u03b1 therapy","volume":"27","author":"Stefan Sleijfer","year":"2005","journal-title":"Pharm. World Sci."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124320_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib43","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124320_bib44","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124320_bib45","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1158\/0008-5472.CAN-23-3971","article-title":"Targeting the TRIM14\/USP14 axis enhances immunotherapy efficacy by inducing autophagic degradation of PD-L1","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124320_bib46","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1038\/s41467-020-17637-z","article-title":"A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124320_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202510936","article-title":"Peptide coacervates with metal-phenolic membranes modulate glucose metabolism and enhance cancer immunotherapy","volume":"37","author":"Zheng","year":"2025","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124320_bib48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41590-022-01262-7","article-title":"Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy","volume":"23","author":"Boukhaled","year":"2022","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124320_bib49","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFN\u03b1 potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124320_bib50","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","article-title":"Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance","volume":"72","author":"Meng","year":"2023","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124320_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202413392","article-title":"An OMV-based nanovaccine as antigen presentation signal enhancer for cancer immunotherapy","volume":"37","author":"Lu","year":"2025","journal-title":"Adv. Mater."},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124320_bib52","doi-asserted-by":"crossref","first-page":"26320","DOI":"10.1002\/anie.202108342","article-title":"Genetically programmable fusion cellular vesicles for cancer immunotherapy","volume":"60","author":"Meng","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124320_bib53","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","article-title":"T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy","volume":"16","author":"Zhai","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124320_bib54","article-title":"Truncated PD1 engineered gas-producing extracellular vesicles for ultrasound imaging and subsequent degradation of PDL1 in tumor cells","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv. Sci."},{"issue":"43","key":"10.1016\/j.biomaterials.2026.124320_bib55","article-title":"Lysosome-targeting bacterial outer membrane vesicles for tumor specific degradation of PD-L1","volume":"20","author":"Ji","year":"2024","journal-title":"Small"},{"issue":"44","key":"10.1016\/j.biomaterials.2026.124320_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202404889","article-title":"Engineered cellular vesicles displaying glycosylated nanobodies for cancer immunotherapy","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124320_bib57","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124320_bib58","doi-asserted-by":"crossref","first-page":"12295","DOI":"10.1021\/acsnano.4c01229","article-title":"Genetically edited Cascade nanozymes for cancer immunotherapy","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226003443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226003443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:27:37Z","timestamp":1785360457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226003443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":58,"alternative-id":["S0142961226003443"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124320","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modularly designed hybrid vesicles as dual-adjuvant nanovaccines for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124320"}}